PT1294363E - Formas de comprimido para aumentar a retencao gastrica de formas de dosagem orais dilataveis de libertacao controlada - Google Patents

Formas de comprimido para aumentar a retencao gastrica de formas de dosagem orais dilataveis de libertacao controlada

Info

Publication number
PT1294363E
PT1294363E PT01914515T PT01914515T PT1294363E PT 1294363 E PT1294363 E PT 1294363E PT 01914515 T PT01914515 T PT 01914515T PT 01914515 T PT01914515 T PT 01914515T PT 1294363 E PT1294363 E PT 1294363E
Authority
PT
Portugal
Prior art keywords
forms
dilatable
tablet
increase
approval
Prior art date
Application number
PT01914515T
Other languages
English (en)
Inventor
Bret Berner
Jenny Louie-Helm
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24394064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1294363(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of PT1294363E publication Critical patent/PT1294363E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
PT01914515T 2000-06-20 2001-02-26 Formas de comprimido para aumentar a retencao gastrica de formas de dosagem orais dilataveis de libertacao controlada PT1294363E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/598,061 US6488962B1 (en) 2000-06-20 2000-06-20 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms

Publications (1)

Publication Number Publication Date
PT1294363E true PT1294363E (pt) 2004-04-30

Family

ID=24394064

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01914515T PT1294363E (pt) 2000-06-20 2001-02-26 Formas de comprimido para aumentar a retencao gastrica de formas de dosagem orais dilataveis de libertacao controlada

Country Status (15)

Country Link
US (1) US6488962B1 (pt)
EP (1) EP1294363B1 (pt)
JP (4) JP2003535886A (pt)
KR (1) KR100716756B1 (pt)
AT (1) ATE256455T1 (pt)
AU (2) AU2001239893B2 (pt)
CA (1) CA2412671C (pt)
DE (1) DE60101581T2 (pt)
DK (1) DK1294363T3 (pt)
ES (1) ES2213108T3 (pt)
IL (2) IL153464A0 (pt)
MX (1) MXPA02012614A (pt)
NZ (1) NZ523214A (pt)
PT (1) PT1294363E (pt)
WO (1) WO2001097783A1 (pt)

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1067910T3 (da) * 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
CZ20023167A3 (cs) * 2000-02-29 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinu a klaritromycinového meziproduktu, v podstatě prostého oximu a farmaceutický prostředek, který jej obsahuje
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP1322158B1 (en) * 2000-10-02 2012-08-08 USV Ltd. Sustained release pharmaceutical compositions containing metformin and method of their production
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
WO2003035039A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8128957B1 (en) * 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004010970A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
WO2004019907A1 (en) * 2002-08-29 2004-03-11 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20040151772A1 (en) * 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
BRPI0406749A (pt) 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
ES2307003T3 (es) * 2003-03-26 2008-11-16 Egalet A/S Composiciones matriciales para el suministro controlado de sustancias medicamentosas.
EP1610767B1 (en) * 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
US8048169B2 (en) 2003-07-28 2011-11-01 Baronova, Inc. Pyloric valve obstructing devices and methods
US9498366B2 (en) 2003-07-28 2016-11-22 Baronova, Inc. Devices and methods for pyloric anchoring
US9700450B2 (en) 2003-07-28 2017-07-11 Baronova, Inc. Devices and methods for gastrointestinal stimulation
US8821521B2 (en) 2003-07-28 2014-09-02 Baronova, Inc. Gastro-intestinal device and method for treating addiction
US6994095B2 (en) * 2003-07-28 2006-02-07 Medventure Associates Iv Pyloric valve corking device and method
US20090259236A2 (en) 2003-07-28 2009-10-15 Baronova, Inc. Gastric retaining devices and methods
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
ATE454138T1 (de) 2003-08-08 2010-01-15 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
US20080089933A1 (en) 2006-10-16 2008-04-17 Amir Alon Device and method for reducing calorie intake
WO2005107713A2 (en) * 2004-05-11 2005-11-17 Egalet A/S Swellable dosage form comprising gellan gum
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US7347868B2 (en) 2004-10-26 2008-03-25 Baronova, Inc. Medical device delivery catheter
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CN101188999B (zh) * 2005-06-03 2012-07-18 尹格莱特股份有限公司 用于递送分散在分散介质中的活性物质的药物传递系统
EP1919466B9 (en) 2005-07-11 2012-05-16 Cortria Corporation Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20070077305A1 (en) * 2005-10-03 2007-04-05 Le Tien C Biocompatible polymeric matrix and preparation thereof
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2185084A4 (en) 2007-09-07 2017-08-09 Baronova, Inc. Device for intermittently obstructing a gastric opening and method of use
BRPI0821732A2 (pt) 2007-12-17 2015-06-16 Labopharm Inc Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
WO2009086119A2 (en) * 2007-12-20 2009-07-09 7L, Llc Swallowable self-expanding gastric space occupying device
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
JP5607550B2 (ja) 2008-03-11 2014-10-15 ディポメド,インコーポレイティド 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
SI2273983T1 (sl) 2008-05-09 2016-11-30 Gruenenthal Gmbh Postopek za pripravo intermediatne praškaste formulacije in končne trdne odmerne oblike z uporabo stopnje strjevanja z razprševanjem
AU2009281752B2 (en) * 2008-08-15 2016-11-17 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
EP2349221A4 (en) * 2008-10-08 2013-03-27 Bioplus Life Sciences Pvt Ltd DELIVERING MEDICATION DELIVERY SYSTEM
EP2367541B1 (en) 2008-12-16 2014-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010129686A1 (en) 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
WO2011004799A1 (ja) 2009-07-06 2011-01-13 杏林製薬株式会社 中空構造を有する錠剤
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
US20110052700A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
CA2783342A1 (en) * 2009-12-08 2011-06-16 Depomed, Inc. Gastric retentive pharmaceutical compositions for extended release of polypeptides
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US20120322782A1 (en) * 2010-02-24 2012-12-20 Pfizer Inc Veterinary compositions
EP2544666A2 (en) 2010-03-09 2013-01-16 Council of Scientific and Industrial Research Gastroretentive, extended release composition of therapeutic agent
EP2590633B1 (en) 2010-07-05 2017-10-11 Jagotec AG Dosage form
AU2011289407B2 (en) 2010-08-11 2015-06-18 Philadelphia Health & Education Corporation Novel D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
EP2621487B1 (en) 2010-09-28 2017-05-03 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
US9962275B2 (en) 2010-10-07 2018-05-08 Randy Louis Werneth Temporary gastric device (TGD) and method of use
US8383135B2 (en) 2010-12-03 2013-02-26 Richard C. Fuisz Solid dosage form that promotes reliable oral, esophageal and GI transit
WO2012078633A2 (en) 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
WO2012080833A2 (en) 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US8722066B2 (en) 2011-03-29 2014-05-13 Primigenia, LLC Devices and methods for weight control and weight loss
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
WO2012169677A1 (ko) * 2011-06-09 2012-12-13 주식회사 비씨월드제약 위 체류 및 방출 조절을 위한 조성물
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
TWI622578B (zh) 2011-12-21 2018-05-01 諾維拉治療公司 B型肝炎抗病毒劑
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
JP6397407B2 (ja) 2012-07-19 2018-09-26 ドレクセル ユニバーシティ 細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド
WO2014026013A2 (en) 2012-08-09 2014-02-13 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
AU2013318182C1 (en) 2012-09-18 2022-01-20 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3756669A1 (en) 2013-01-07 2020-12-30 The Trustees of the University of Pennsylvania Compositions for use for treating cutaneous t cell lymphoma
AU2014235521B2 (en) 2013-03-15 2018-01-04 Baronova, Inc. Locking gastric obstruction device and method of use
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN106414752A (zh) 2013-07-02 2017-02-15 桉树脑有限责任公司 具有抗微生物活性的挥发性有机化合物制剂
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
JP6932506B2 (ja) 2013-11-26 2021-09-08 イエール ユニバーシティ 細胞透過組成物およびそれを用いる方法
MX369956B (es) 2013-12-03 2019-11-27 Auspex Pharmaceuticals Inc Metodos para preparar compuestos de benzoquinolina.
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
WO2015157262A1 (en) 2014-04-07 2015-10-15 Women & Infants Hospital Of Rhode Island Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
AU2015271808A1 (en) 2014-06-02 2016-12-08 Clexio Biosciences Ltd. Expandable gastroretentive dosage form
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CN106573015B (zh) 2014-06-11 2021-11-26 麻省理工学院 肠溶弹性体
WO2016028753A1 (en) 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
EP3258916A1 (en) 2015-02-20 2017-12-27 Osmotica Kereskedelmi ES Szolgaltato KFT Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
IL305352A (en) 2015-03-06 2023-10-01 Auspex Pharmaceuticals Inc Methods for treating abnormal movement disorders
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
CN107592803B (zh) 2015-05-01 2021-01-22 麻省理工学院 可触发形状记忆感应装置
US10597368B2 (en) 2015-05-08 2020-03-24 Brown University Syringolin analogues and methods of making and using same
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
WO2017003822A1 (en) 2015-06-30 2017-01-05 Galleon Pharmaceuticals, Inc. Novel breathing control modulating compounds, and methods of making and using same
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3364946A4 (en) 2015-10-23 2019-06-26 Lyndra, Inc. STOMACH DISTRIBUTION SYSTEMS FOR DELAYED RELEASE OF THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
WO2017075145A1 (en) 2015-10-28 2017-05-04 Yale University Quinoline amides and methods of using same
US20180371434A1 (en) 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
MX2018011278A (es) 2016-03-17 2019-07-08 Thiogenesis Therapeutics Inc Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
WO2017190001A1 (en) 2016-04-29 2017-11-02 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
WO2018045229A1 (en) 2016-09-01 2018-03-08 Mebias Discovery Llc Substituted ureas and methods of making and using same
WO2018064630A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
KR102522060B1 (ko) 2016-11-07 2023-04-14 아뷰터스 바이오파마 코포레이션 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
EP3547974B1 (en) 2016-12-02 2023-11-15 Clexio Biosciences Ltd. Gastric residence system
EP3571196B1 (en) 2017-01-19 2023-01-04 Temple University Of The Commonwealth System Of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
WO2018213588A1 (en) 2017-05-17 2018-11-22 Massachusetts Institute Of Technology Tissue anchoring articles
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
ES2928071T3 (es) 2017-06-16 2022-11-15 Amneal Complex Products Res Llc Formas de dosificación gastrorretentiva para el suministro sostenido de fármacos
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
WO2019023621A1 (en) 2017-07-28 2019-01-31 Yale University ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
CN111527103A (zh) 2017-09-08 2020-08-11 科罗拉多大学董事会,法人团体 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
CN111683684A (zh) 2017-09-20 2020-09-18 硫创治疗公司 用于治疗半胱胺敏感性病症的方法
WO2019104316A1 (en) 2017-11-27 2019-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, compositions, and methods for treating and/or preventing periodontal disease
JP7296084B2 (ja) 2017-12-04 2023-06-22 クレキシオ バイオサイエンシーズ エルティーディー. 長時間作用型胃滞留システム
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CA3086153A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
SG11202006994XA (en) 2018-01-24 2020-08-28 Univ Rockefeller Antibacterial compounds, compositions thereof, and methods using same
WO2019222570A1 (en) 2018-05-17 2019-11-21 Massachusetts Institute Of Technology Systems for electrical stimulation
EP3802524A1 (en) 2018-05-29 2021-04-14 Cersci Therapeutics, Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
JP7048770B2 (ja) 2018-06-18 2022-04-05 アムニール コンプレックス プロダクツ リサーチ エルエルシー ピリドスチグミンを含む持続放出組成物
EP3810111A4 (en) 2018-06-19 2022-03-23 National University of Singapore FORMULATIONS OF 5-HYDROXYTRYPTOPHAN (5-HTP) FOR BETTER BIOAVAILABILITY FOR DIFFERENT INDICATIONS
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
MX2021008966A (es) 2019-01-30 2021-11-04 Sanifit Therapeutics S A Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
JP2022523121A (ja) 2019-02-01 2022-04-21 マサチューセッツ インスティテュート オブ テクノロジー 液体注入のためのシステムおよび方法
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
KR102068616B1 (ko) * 2019-03-15 2020-01-21 (주)한국원자력 엔지니어링 장내 체류를 위한 내용물 운반체
US11524048B2 (en) 2019-05-09 2022-12-13 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
US11511093B2 (en) 2019-10-11 2022-11-29 Wonkwang University Center for Industry Academy Cooperation Gastroretentive drug delivery device having expandable structure and manufacturing method therefor
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
MX2022015772A (es) 2020-06-09 2023-05-19 Inozyme Pharma Inc Proteínas enpp1 o enpp3 solubles y sus usos.
AU2021396978A1 (en) 2020-12-08 2023-02-23 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
CN116801868A (zh) 2021-07-30 2023-09-22 埃维西亚治疗公司 5-羟色氨酸胃滞留剂型
WO2023064598A1 (en) 2021-10-14 2023-04-20 Evecxia Therapeutics, Inc. A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253554A3 (en) * 1986-07-15 1988-07-20 Pfizer Inc. Controlled release drug-containing fibers
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
CN1108150C (zh) * 1994-05-13 2003-05-14 史密丝克莱恩比彻姆公司 增加钙摄取的方法及所用的制剂
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
EP1003476B1 (en) * 1997-08-11 2004-12-22 ALZA Corporation Prolonged release active agent dosage form adapted for gastric retention
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms

Also Published As

Publication number Publication date
JP2013224324A (ja) 2013-10-31
CA2412671A1 (en) 2001-12-27
EP1294363A1 (en) 2003-03-26
IL153464A0 (en) 2003-07-06
IL153464A (en) 2011-04-28
CA2412671C (en) 2006-10-03
KR20030023876A (ko) 2003-03-20
JP2016166239A (ja) 2016-09-15
ES2213108T3 (es) 2004-08-16
JP2009040787A (ja) 2009-02-26
AU2001239893B2 (en) 2004-11-18
MXPA02012614A (es) 2003-04-10
DE60101581D1 (de) 2004-01-29
WO2001097783A1 (en) 2001-12-27
EP1294363B1 (en) 2003-12-17
DK1294363T3 (da) 2004-04-13
DE60101581T2 (de) 2004-09-16
KR100716756B1 (ko) 2007-05-14
US6488962B1 (en) 2002-12-03
ATE256455T1 (de) 2004-01-15
NZ523214A (en) 2003-08-29
AU3989301A (en) 2002-01-02
JP2003535886A (ja) 2003-12-02

Similar Documents

Publication Publication Date Title
PT1294363E (pt) Formas de comprimido para aumentar a retencao gastrica de formas de dosagem orais dilataveis de libertacao controlada
IL150568A0 (en) A controlled release oral drug dosage form
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
CY1105319T1 (el) Ταχεως αποσαθρουμενη απο του στοματος συνταγοποιηση του valdecoxib
ECSP109873A (es) Mezclas secas de material para construcción modificadas con polímero
MX2009006056A (es) Formulacion de matriz sensible al ph.
CY1105050T1 (el) Συνθεσεις διπλης-απελευθερωσης ενος αναστολεα κυκλοοξυγενασης-2
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
ATE106717T1 (de) Orale heilmittelform für dauerverabreichung.
NO20024238D0 (no) Peptidase-spaltbare, målsökende antineoplastiske medikamenter, og deres terapautiske anvendelse
ATE477795T1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
FI5842U1 (fi) Farmaseuttinen annosmuoto, joka käsittää suuren määrän lääkerakeita
ECSP088097A (es) Nuevos regímenes para dispositivos de administración controlada de fármacos para anticoncepción
DE602005020796D1 (de) Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
NO20063308L (no) Kombinasjon av flupirtin og tramadol
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
NO20040611L (no) Ekspanderbar gastrisk retensjonsanordning.
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
NO20051261L (no) Morfin-6-glukuronidsalt
DK0876142T3 (da) Topisk tilførsel af lægemidler til den nedre mavetarmkanal
NO20024363D0 (no) Nye LHRH-antagonister, produksjon og anvendelse av disse som medikamant
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.